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Abstract: The aim of this study was to investigate the effects of local administration of fluvastatin-gelatin
complex on the healing of bone defects in low-turnover osteoporosis mice. Gelatin was used as a carrier of the
fluvastatin. A fluvastatin-gelatin complex solution was created by dissolving each concentration of fluvastatin
in a 75mg/mL gelatin solution. The gelatin solution was mixed with air, then lyophilized for 1 day and cross-
linked by dry heating to make a fluvastatin-gelatin complex sponge. After crosslinking, the complex sponge
was cut into pieces 1 mm diameter × 1 mm high to fit the bone defect area. The amount of fluvastatin in the
sponge was adjusted to control (0 nmol), 0.1 nmol, 0.2 nmol, and 0.4 nmol. Using 20-week-old low-turnover
osteoporosis model mice (SAMP6) and normal model mice (SAMR1), cylindrical and bone defects were made
in sites 1.0 mm in diameter and depth, 1 mm of 3 mm from both sides of the distal end of the femur. The
complex sponge was then inserted into each site, and the wound was closed. Radiographic analysis and histologic
examinations were then performed. In SAMP6, the bone volumes of the bone defect areas in the 0.1nmol and
0.2nmol groups were significantly higher compared with those of the control and 0.4nmol groups at 14 and 21
days. Histological observation showed that the volume of newly formed bone increased in the 0.1nmol and
0.2nmol groups compared to those in the control and 0.4nmol groups at 14 and 21 days. The bone volumes of
newly formed bone in SAMR1 were higher than were those in SAMP6, and the optimum concentration of
fluvastatin was different between SAMP6 and SAMR1. The present study suggests that local administration of
a fluvastatin-gelatin complex sponge provides improvement in bone healing in low-turnover osteoporosis.
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Introduction
One of the well-known risk factors of prognosis for dental
implants is osteoporosis, which has two types, high-turnover
osteoporosis and low-turnover osteoporosis1). Many studies on
low-turnover osteoporosis have used the senescence-accelerated
mouse prone 6 (SAMP6) strain of mice, a type that develops low-
turnover osteoporosis2). In particular, low-turnover osteoporosis
has been reported to decrease the density of both cortical bone
and trabecular bone and peri-implant bone3). Accordingly,
investigation of low-turnover osteoporosis is considered to be
important for dental implant treatment all of elderly people.
Statins are competitive inhibitors of 3-hydroxy-2-methyl-
glutaryl coenzyme A (HMG-CoA) reductase, and are widely used
to lower cholesterol levels, which is an important factor in the
treatment of hyperlipidemia and arteriosclerosis4). Recently,
another in vivo effect of statins has also attracted attention, with
a number of studies finding that statins promote the differentiation
of osteoblasts produced by stimulation with bone morphogenetic
protein-2 (BMP-2), indicating their potential in the development
of new osteogenic drugs5-8).
However, the high dose of systemic administration of statins
presents a serious problem with risks such as rhabdomyolysis9,10).
Accordingly, the local administration may be recommended for
enhancing the bone formation in jawbone8). Previous experiments
by our group have shown that local administration of fluvastatin,
one of the statins, promotes osteogenesis in normal rat bone defect
models using a fluvastatin-gelatin complex11,12). In our previous
study, influence of the local administration of fluvastatin on bone
healing was evaluated in a senile osteoporosis model rat13).
However, no study was reported about the local administration of
statins on bone healing using low-turnover osteoporosis model
mice.
In this study, the effect of local administration of fluvastatin
on bone healing in low-turnover osteoporosis model mice and
senescence-accelerated mouse resistant mice as a normal model
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was evaluated radiologically and histologically using a fluvastatin-
gelatin complex. The overall objective of this study was to
investigate the effects of the local administration of fluvastatin
on the healing of bone defects in low-turnover osteoporosis.
Materials and Methods
Preparation of fluvastatin-gelatin complex sponge
An alkaline gelatin (isoelectric point of 7.0–9.0, Nitta Gelatin,
Osaka, Japan) and fluvastatin sodium salt (Toronto Research
Chemicals Inc., Ontario, Canada) were used in this study.
The gelatin was dissolved in ultra-pure water to make a 75
mg/mL gelatin solution, and then the fluvastatin was dissolved in
the gelatin solution to make a fluvastatin-gelatin complex solution.
Subsequently, one syringe containing 1 ml of the fluvastatin-
gelatin complex solution was connected with another syringe with
2 ml of air using a syringe connector, and the solutions were
foamed by an emulsion preparation method similar to making an
adjuvant emulsion14).
The solutions were successively lyophilized for 1 day, and
then cross-linked by dry heating (125 °C, 30 min) to make
fluvastatin-gelatin complex sponge. After crosslinking, the
complex sponge was cut into pieces 1.0 mm in diameter and height
to fit the bone defect area. The amount of fluvastatin in a sponge
was adjusted to 0.1 nmol, 0.2 nmol, and 0.4 nmol. A gelatin sponge
without fluvastatin (0 nmol) was used as a control.
Fig. 1 is a SEM image of the sponge with its porous structure
with pore diameters of approximately 200 μm.
Animal experiment
Twenty-week-old male senescence-accelerated mouse
resistant (SAMR1) mice (Japan SLC Inc., Shizuoka, Japan) were
used as a control. SAMP6 mice (Japan SLC Inc., Shizuoka, Japan)
were used as models of low-turnover osteoporosis. Both groups
were allowed food and water ad libitum and maintained on a 12-
h light/dark cycle (lights on from 8:00 to 20:00) at 23±1 °C with
60±10 % humidity during the experiment. Both groups were
anesthetized by intraperitoneal injection (60 mg/kg body weight)
of sodium pentobarbital (Somnopentyl, Kyoritsu Seiyaku Co. Ltd.,
Tokyo, Japan).
The overlying skin of the femur was shaved and disinfected
with iodated alcohol. The outside skin from the central femur to
the knee was incised longitudinally, and the muscles were split to
expose the femur, preserving the sciatic nerve.
A 1.0 mm round bur was used to create a cylindrical bone
defect with 1.0 mm in diameter and depth under constant irrigation
with normal saline solution to prevent overheating of the bone
edges. The bone defect was carefully created 3 mm from the
femoral distal epiphysis while avoiding any damage to the growth
plate (Fig. 2 a). Cortical bone perforation was confirmed by
bleeding from the bone marrow. The complex sponge, selected
randomly was then inserted into each site. After inserted the
complex sponge, the muscle and skin were sutured. The
experimental protocol is shown in Fig. 2 b.
All animals survived and recovered quickly from surgery. The
mice appeared to be in good health throughout the test periods.
All animal experiments in this study were conducted in accordance
with the Tokyo Dental College Guidelines for Animal Experiments
(Approval date: 4/1/2013; Approval number: 253005).
Radiological analysis of chronological change in bone
formation
X-ray micro-CT images were taken using an in vivo 3D micro
X-ray CT System R_mCT (Rigaku Co., Tokyo, Japan). Micro-
CT images were obtained from each mouse immediately after (0
day) and at 7, 14, and 21 days after bone defect creation under
inhalation anesthesia with isoflurane. The samples were set on
the object stage and imaging was performed over a full 360-degree
rotation with an exposure time of 2 min. The conditions for Micro-
CT were as follows: tube voltage, 85 kV; tube current, 160 mA;
magnification, 10×; and slice width, 20 μm.
Representative images for calculating the bone volume (BV)
each day on an identical animal are shown in Fig. 3. Micro-CT
images were taken from the identical animal at 0 day, 7, 14, and
21 days (Fig. 3 a), after which they were merged using TRI/3D-
Bon software (Ratoc System Engineering Co. Ltd., Tokyo, Japan)
with a TRI/3D-Adj optional feature (Ratoc System Engineering
Co. Ltd., Tokyo, Japan) (Fig. 3 b). Chronological changes at 7,
14, and 21 days were calculated by subtracting the 0 day value
from each day’s measurement (Fig. 3 c). A cylindrical region of
interest (ROI) with 1.0mm in diameter and height of the femur
was selected for analysis. The ROI was placed where the original
defect was located, as the margins were visually recognizable.
Mask work was performed to binarize the 3-D data set in the
ROI. Finally, bone volume (BV, mm3) with new bone was
measured directly.
Figure 1. SEM image of gelatin sponge. SEM image of the sponge
with its porous structure with pore diameters of approximately 200 μm
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Figure 2. Bone defect model in mouse femur (a) and experimental protocol (b).
Figure 3. Representative X-ray micro-CT images for calculating the bon volume (BV) at each day on an identical animal. (a): Micro-CT
images at 0day, 7, 14 and 21days; (b): Merged images with three colors: 7 day; blue, 14 days; red, 21 days; green; (c): Subtracted images
0 day from each days;
Histological analysis
Two mice were randomly selected in each groups, and
euthanized on days 14 and 21 after surgery. The femur area
including the bone defect was extirpated. The femurs were fixed
in 10 % neutral buffered formalin at 4 ºC for 1 day and decalcified
with EDTA (pH 7.0-7.5; Wako Pure Chemical Industries, Osaka,
Japan) for 5 days. Paraffin sections 3 µm thick were prepared
and stained with hematoxylin-eosin (H-E) according to the
standard procedure. Histological observation was performed using
a universal microscope (Axiophot 2, Carl Zeiss, Oberkochen,
Germany).
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Statistical analysis
The data were analyzed using a statistical analysis software
package (IBM SPSS Statistics 20, IBM Co., Somers, NY, USA).
The BV values were analyzed using two-way analysis of variance
(ANOVA) with the animal species and the amounts of fluvastatin
as factors. Subsequently, Tukey’s HSD multiple comparisons were
performed between the amounts of fluvastatin.
Results
Radiological analysis of chronological change in bone
formation
Representative micro CT images of SAMR1 at 0, 7, 14, and
21 days are shown in Fig. 4 A. At 7 days, newly formed bone was
hardly observed in the bone defect areas of all groups. At 14 and
21 days, newly formed bone was observed in all groups, and the
amount of newly formed bone in the 0.1 nmol and 0.2 nmol groups
increased relative to that in the control and 0.4 nmol groups.
Representative micro CT images of SAMP6 at 0, 7, 14, and
21 days are shown in Fig. 4 B. At 7 days, newly formed bone was
not recognized in the bone defect areas of all groups. At 14 and
21 days, newly formed bone was observed in all groups. The
amount of newly formed bone increased in the 0.1 nmol and 0.2
nmol groups relative to that in the control and 0.4 nmol groups.
In a comparison of SAMR1 with SAMP6, the cortical bone in
SAMP6 was thinner than that of SAMR1. More newly formed
bone was observed in SAMR1 than in SAMP6.
Fig. 5 shows the chronological changes in BV with new bone
at 7, 14, and 21 days. The BV values of newly formed bone in
SAMR1 were higher than were those in SAMP6 (P<0.05).
In SAMR1, the 0.1 nmol and 0.2 nmol groups yielded
significantly higher BV than did the control group at 14 and 21
days. In contrast, no significant difference was observed between
the control and 0.4 nmol groups. BV increased over time, and
almost reached a peak at 14 days in all groups.
In SAMP6, the 0.1 nmol and 0.2 nmol groups showed
significantly higher BV than did the control group at 14 and 21
days. In contrast, no significant difference was observed between
the control and 0.4 nmol groups. At 21 days, the 0.1 nmol group
showed significantly higher BV than did all other groups. BV
almost reached a peak at 21 days in the control, 0.1 nmol, and 0.2
Figure 4A. Representative micro-CT images of bone defect area at days 0, 7, 14, 21 in SAMR1. At 7 days, newly formed bone was hardly
observed in the bone defect areas of all groups.At 14 and 21 days, newly formed bone was observed in all groups, and the amount of newly
formed bone in the 0.1 nmol and 0.2 nmol groups increased relative to that in the control and 0.4 nmol groups.
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nmol groups.
Histological analysis
Fig. 6 shows the results of histological observation of the newly
formed bone in SAMR1. At day 14, woven bone was formed in
the bone defect area (Fig. 6 a-d). Woven bone of the control and
0.4 nmol groups was observed in cortical bone area (Fig. 6 a, d).
On the other hand, in the 0.1 nmol and 0.2 nmol groups, woven
bone was observed not only in cortical bone area but also in
trabecular bone area (Fig. 6 b, c). At day 21, newly formed bone
has matured in cortical bone area (Fig. 6 e-h). In addition, newly
formed bone had a trabecular bone-like structure under cortical
bone-like structure in the 0.1 nmol and 0.2 nmol groups, (Fig. 6 f,
g)
Fig. 7 shows the results of histological observation of the newly
formed bone in SAMP6. At day 14, woven bone was formed in
the bone defect area (Fig. 7 a-d). Woven bone of the control and
0.4 nmol groups was observed in cortical bone area (Fig. 7a, d).
On the other hand, in the 0.1 nmol and 0.2 nmol groups, woven
bone was observed in not only cortical bone area but also trabecular
bone area (Fig. 7 b, c). At day 21, newly formed bone had matured
in cortical bone area (Fig. 7 e-h). In addition, newly formed bone
had a trabecular bone-like structure under cortical bone-like
structure in the 0.1 nmol and 0.2 nmol groups same as SAMR1(Fig.
7 f, g).
In a comparison of SAMR1 with SAMP6, trabecular bone-
like structure of SAMP6 was thinner than that of SAMR1.
Discussion
In this study, using a fluvastatin-gelatin complex sponge, the
effect of local administration on bone healing of low-turnover
osteoporosis model mice was evaluated. The results showed that
improved bone healing was recognized in the low-turnover
osteoporosis model. Similar results were reported in our previous
study showing that the osteogenic effect of fluvastatin was
extended by using a fluvastatin-gelatin complex in senile
osteoporosis model rats13).
The release characteristics of fluvastatin from the fluvastatin-
gelatin complex sponge were investigated in previous studies15,16).
The results showed that the rate of dissolution of a gelatin sponge
Figure 4B. Representative micro-CT images of bone defect area at days 0, 7, 14, 21 in SAMP6. At 7 days, newly formed bone was not
recognized in the bone defect areas of all groups. At 14 and 21 days, newly formed bone was observed in all groups. The amount of newly
formed bone increased in the 0.1 nmol and 0.2 nmol groups relative to that in the control and 0.4 nmol groups.
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Figure 5. BV valuesin SAMR1 and SAMP6 at 7 days, 14 days, and 21 days.
Figure 6. Histological observation of bone healing process in SAMR1 (CB: cortical bone; NB: new bone). At day 14, woven bone was
formed in the bone defect area (a-d). Woven bone of control and 0.4 nmol groups was observed in cortical bone area (a, d). On the
other hand, in 0.1 nmol and 0.2 nmol groups, woven bone was observed in not only cortical bone area but also trabecular bone area (b,
c). At day 21, newly formed bone has matured in cortical bone area (e-h). In addition, newly formed bone had a trabecular bone-like
structure under cortical bone-like structure in 0.1 nmol and 0.2 nmol groups, (f, g).
Figure 7 .Histological observation of bone healing process in SAMP6 (CB: cortical bone; NB: new bone). At day 14, woven bone was
formed in the bone defect area (a-d). Woven bone of control and 0.4 nmol groups was observed in cortical bone area (a, d). On the other
hand, in 0.1 nmol and 0.2 nmol groups, woven bone was observed in not only cortical bone area but also trabecular bone area (b, c). At
day 21, newly formed bone newly formed bone have matured in cortical bone area (e-h). In addition, newly formed bone had a
trabecular bone-like structure under cortical bone-like structure in 0.1 nmol and 0.2 nmol groups same as SAMR1 (f, g).
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is controllable by changing the rate of thermal cross-linking.
Accordingly, the time of dissolution of the gelatin could be
extended by controlling the rate of thermal cross-linking over three
days. In addition, since the fluvastatin and gelatin were combined
electrically, fluvastatin is believed to be released gradually with
the dissolving gelatin. Indeed, the wide-range degradation of the
fluvastatin-gelatin complex sponge was recognized in the bone
defect areas in this study. These results suggest that the release of
fluvastatin occurred gradually and that the released fluvastatin
may have pharmaceutical efficacy for bone healing. Another
advantage of the fluvastatin-gelatin complex sponge is easy
handling, leading to convenience in clinical applications.
In this study, fluvastatin was used to investigate the effect of
the local administration of statins. Hydrophobic statins
(simvastatin, lovastatin) enter the liver via the hepatic portal vein,
while hydrophilic statins (rosuvastatin, pravastatin, fluvastatin)
require active transport into the cell17). Simvastatin is administered
by gavage and requires hepatic conversion to metabolically active
β-hydroxy acid to become medicinally active. Therefore, for local
administration, simvastatin must first be hydrolyzed to form
simvastatin acid18,19). The structure of fluvastatin is significantly
different from those of previously used HMG-CoA reductase
inhibitors such as the pravastatin and simvastatin metabolites,
which are derived from fungi20,21). Therefore, it was considered
that fluvastatin might have a pharmacological effect on bone
formation in addition to the main effect of HMG-CoA reductase
inhibitory activity. Some authors reported the positive effect of
locally applied fluvastatin on bone6,11,12). However, the mechanisms
of the osteogenic effect of fluvastatin are not entirely clear.
Significant increases of BV as well as newly formed bone in
histological observation were recognized in the 0.1 nmol and 0.2
nmol groups at 14 and 21 days using micro-CT analysis of SAMR1
in this study. In the 0.4 nmol group, however, the amount of new
bone formation was lower than was that in the 0.1 nmol and 0.2
nmol groups for 21 days. This result indicates that high-dose
fluvastatin inhibits bone healing. Several studies have reported
that a high dose of simvastatin inhibits bone healing because of
the induction of inflammation22,23). These high-dose-induced
inflammations were suggested as inhibiting bone healing. Our
results agreed with these reports.
The cortical bone in SAMP6 used in this study was thinner
than that of SAMR1 on the micro-CT images. That attribute is
considered to be caused by the mouse species, that is, the thin
cortical bone in SAMP6 represents a typical feature of the SAMP6
mouse. Furthermore, BV in SAMP6 were lower than were those
in SAMR1 in this study. This result is believed to be due to
osteoblastic hypoplasia that inhibits the healing of bone defects2,24).
The optimum concentration of fluvastatin was different
between the SAMP6 and SAMR1 mice in this study. This may be
due to the different susceptibility of the fluvastatin by SAMP6
and SAMR1. Further studies are necessary to clarify the dose-
dependent effect of fluvastatin on normal and osteoporosis models
in vitro. In addition, for clinical applications, it is necessary to
determine the optimum doses of fluvastatin carefully.
In conclusion, the present study revealed that local
administration of a fluvastatin-gelatin complex sponge improved
bone healing in low-turnover osteoporosis.
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